【摘要】 目的 :在阿莫西林中加入不同比例的他唑巴坦后 ,观察其对临床分离的128株致病菌的体外抗菌活性 ,并与阿莫西林/舒巴坦、阿莫西林/克拉维酸比较抗菌活性的强弱。方法 :用2倍稀释法检测4种抗菌药物对临床分离的128株致病菌的体外抗菌活性。结果 :阿莫西林/他唑巴坦 (2∶1)的MIC50 值分别是阿莫西林/他唑巴坦 (4∶1)与 (8∶1)的1/4～1/8 ,是阿莫西林/克拉维酸(2∶1)及阿莫西林/舒巴坦 (2∶1)的1/2～1/4 ;其MIC90 值分别是阿莫西林/他唑巴坦 (4∶1)与 (8∶1)的相同值或1/4 ,是阿莫西林/克拉维酸 (2∶1)与阿莫西林/舒巴坦 (2∶1)的1/2～1/4。结论 :与其它联合制剂相比 ,阿莫西林/他唑巴坦抗菌作用最强 ,并且其2∶1的比例体外抗菌效果最好。更多还原

【Abstract】 OBJECTIVE:Using in vitro studies,we evaluated the antibacterial activity of amoxicillin/tazobactam against 128 strains of pathogens isolated from patients and compared with amoxicillin/clavulanic acid and amoxicillin/sulbactam.METHODS:To detect the minimum inhibitory concentrations (MIC)of four β-lactams against 128 clinically isolated strains with agar dilution method.RESULTS:The results indicated that the in vitro antibacterial activity of amoxicillin/tazobactam(2∶1) was the best.The MIC50 of amoxicillin/tazobactam(2∶1) is 1/4～1/8 times than those of amoxicillin/sulbutam and amoxicillin/clavulanic acid.The MIC90 of amoxicillin/tazobactam(2∶1) was 1/2～1/4 of those of amoxicillin/sulbutam and amoxicillin/clavulanic acid.The combination ratio 2∶1(amoxicillin/tazobactam)of the two compounds was more suitable than other combination ratios(4∶1 and 8∶1)for inactivating β-lactamase.CONCLUSION:The in vitro antibacterial activities of amoxicillin/tazobactam(2∶1) against MRSA,MRSE,MSSA and E.coli are high.It showed that amoxicillin/tazobactam(2∶1)is stable to β-lactamase and is an effective bactericidal agent.更多还原